VistaGen Therapeutics
在场
VistaGen Therapeutics 是一家在股票代码 VTGN (US) 下上市的公司。
高管
查看带有其 22 名主要高管的组织结构图
VistaGen Therapeutics 搜索最多的简介
- Shawn Singh, Chief Executive Officer and Director
- Mary Rotunno, Director
- Maggie Fitzpatrick, Director
创建提醒
跟踪 VistaGen Therapeutics 的高管变动
生物技术
VistaGen Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
VistaGen Therapeutics 的最新新闻稿
- VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B | VistaGen Therapeutics, Inc
- VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit | VistaGen Therapeutics, Inc
- VistaGen to Participate at William Blair Biotech Focus Conference 2022 | VistaGen Therapeutics, Inc
- VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update | VistaGen Therapeutics, Inc
- VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022 | VistaGen Therapeutics, Inc
- VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting | VistaGen Therapeutics, Inc
- VistaGen to Participate in Upcoming June Investor Conferences | VistaGen Therapeutics, Inc
- VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Appoints Reid Adler as Chief Legal Officer | VistaGen Therapeutics, Inc
- View more press releases Close
通过电子邮件
